Sharon Glaysher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sharon Glaysher has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ian A. Cree
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
2 shared publications - Ajit Narayanan
School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland 1010, New Zealand
1 shared publication - Augusta Fernando
Translational Oncology Research Centre, Queen Alexandra Hospital, The Pathology Centre, Portsmouth, PO6 3LY, UK
1 shared publication - Bruce Addis
Departments of Thoracic Surgery and Pathology, Southampton General Hospital, Southampton, UK
1 shared publication - Christian M. Kurbacher
Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany
1 shared publication - D.Hadji Yiannakis
Departments of Thoracic Surgery, Oncology and Pathology, Derriford Hospital, Plymouth, UK
1 shared publication
Latest Publications
- Open Access
- 27 August 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 300
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems. This study has tested the hypothesis that the molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors.
- 27 August 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 300
Open AccessResistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems. This study has tested the hypothesis that the molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors.
- Open Access
- 28 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 38
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effectsin vitroand in patients. We have examined the effect of fluvastatin alone and in combination with zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly against breast cancer. The combination of zoledronic acid and fluvastatin was more active than either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell effects. A clinical trial to test this is in preparation.
- 28 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 38
Open AccessActivity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effectsin vitroand in patients. We have examined the effect of fluvastatin alone and in combination with zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly against breast cancer. The combination of zoledronic acid and fluvastatin was more active than either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell effects. A clinical trial to test this is in preparation.